Quantum BioPharma Ltd. (NASDAQ: QNTM) is advancing its lead candidate Lucid-MS toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (MS) following U.S. Food and Drug Administration clearance of its Investigational New Drug application. The FDA’s acceptance of the IND marks a critical regulatory milestone for the company, allowing it to proceed with clinical testing in patients. Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2) designed to target demyelination directly rather than suppress the immune system, a mechanism that differentiates it from most existing MS therapies.
The importance of this announcement lies in its potential to address a significant unmet need in MS treatment. Current therapies largely focus on immunomodulation, which can reduce relapses but do not directly promote myelin repair. By inhibiting PAD2, Lucid-MS aims to prevent and reverse myelin degradation, the underlying pathology of MS. Preclinical models have shown the compound to be effective in preventing and reversing myelin degradation, suggesting a disease-modifying approach that could complement or replace existing treatments. If successful in phase 2, Lucid-MS could become the first therapy to directly target the root cause of disability progression in MS.
Quantum BioPharma’s research collaboration with Massachusetts General Hospital and Harvard Medical School further strengthens its scientific foundation. The collaboration involves the [¹⁸F]3F4AP PET imaging tracer, which is being evaluated as a method to visualize and measure demyelination. This imaging tool could provide a objective biomarker for assessing treatment response in MS trials, potentially accelerating drug development and enabling more precise patient selection. The ability to measure demyelination directly would be a major advance for both clinical research and patient care.
The broader biopharmaceutical landscape includes several companies advancing therapies in areas of unmet medical need. Novartis AG (NYSE: NVS) recently received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia. Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These developments underscore the industry’s focus on innovative mechanisms, and Quantum BioPharma’s progress with Lucid-MS places it among companies pursuing high-impact therapies.
For Quantum BioPharma, the FDA clearance and planned phase 2 trial represent a key inflection point. The company retains full rights to Lucid-MS and has a portfolio that includes UNBUZZD™, an alcohol misuse product spun out to Unbuzzd Wellness Inc., in which Quantum holds a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. The advancement of Lucid-MS, however, remains the most significant near-term value driver.
Investors and patients alike will be watching the phase 2 trial design and timeline, as positive results could validate a novel mechanism for treating MS and open partnership or licensing opportunities. The full press release can be viewed at https://ibn.fm/lCey9. Additional news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
